Invesaro

Stocks RNTX Earnings

Earnings

Rein Therapeutics, Inc. (RNTX) earnings

Quarterly results of Rein Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when RNTX files with the SEC.

Next earnings date

Rein Therapeutics, Inc. is expected to report around November 13, 2026. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q2 FY2026

In Q2 FY2026 (ended June 30, 2026) Rein Therapeutics, Inc. reported revenue of $0 and a net loss of $6.4M.

Diluted earnings per share were -$0.10.

Filed with the SEC on August 14, 2026.

Revenue by quarter
Q3 24: $0 $0 Q3 24Q4 24: $0 $0 Q4 24Q1 25: $0 $0 Q1 25Q2 25: $0 $0 Q2 25Q3 25: $0 $0 Q3 25Q4 25: $0 $0 Q4 25Q1 26: $0 $0 Q1 26Q2 26: $0 $0 Q2 26
Net income by quarter
Q3 24: -$5.8M -$5.8M Q3 24Q4 24: -$41M -$41M Q4 24Q1 25: -$5.5M -$5.5M Q1 25Q2 25: -$6.8M -$6.8M Q2 25Q3 25: -$5.6M -$5.6M Q3 25Q4 25: -$32M -$32M Q4 25Q1 26: -$5.8M -$5.8M Q1 26Q2 26: -$6.4M -$6.4M Q2 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q2 FY2026June 30, 2026$0--$6.4M-$0.10
Q1 FY2026March 31, 2026$0--$5.8M-$0.19
Q4 FY2025December 31, 2025$0--$32M-
Q3 FY2025September 30, 2025$0--$5.6M-$0.21
Q2 FY2025June 30, 2025$0--$6.8M-$0.28
Q1 FY2025March 31, 2025$0--$5.5M-$0.25
Q4 FY2024December 31, 2024$0--$41M-
Q3 FY2024September 30, 2024$0--$5.8M-$0.27

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Rein Therapeutics, Inc.'s next earnings date?

Rein Therapeutics, Inc. is expected to report around November 13, 2026. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Rein Therapeutics, Inc.'s latest quarterly results?

For Q2 FY2026, which ended June 30, 2026, Rein Therapeutics, Inc. reported revenue of $0 and a net loss of $6.4M. The figures come from its filing with the SEC.

Get an email when RNTX reports

Follow RNTX and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when RNTX files with the SEC.

Source: quarterly figures Rein Therapeutics, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Rein Therapeutics, Inc.